JPRN-UMIN000042946招募中未知
Efficacy and Safety of Nintedanib in Idiopathic Pleuroparenchymal Fibroelastosis (Phase 2 trial) - Efficacy and Safety of Nintedanib in Idiopathic Pleuroparenchymal Fibroelastosis (Phase 2 trial)
Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences Tokushima University0 个研究点目标入组 10 人开始时间: 2021年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Have a history of treatment either with pirfenidone or nintedanib NAC, prednisone > 15 mg/day or equivalent, azathioprine, cyclosporine or cyclophosphamide received within 8 weeks of visit 1 Have airway obstruction Have lung cancer Have pulmonary hypertension Developed acute exacerbation within 3 months of visit 1 etc.
研究者
相似试验
进行中（未招募）
1 期
Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREHereditary Hemorrhagic TelangiectasiaMedDRA version: 20.1Level: LLTClassification code 10019887Term: Hereditary hemorrhagic telangiectasiaSystem Organ Class: 100000004850EUCTR2019-002593-31-FRHospices Civils de Lyon60
招募中
不适用
Efficacy and safety of nintedanib for progressive fibrosing interstitial diseases in single center cohort studyJPRN-UMIN000042254Japanese Red Cross Medical Center40
招募中
不适用
The safety and efficacy of nintedanib for patients with progressive fibrosing interstitial lung disease in a real world setting-a prospective observational studyProgressive fibrosing interstitial lung diseaseJPRN-UMIN000041380Department of Respiratory Medicine, Juntendo University Hospital300
招募中
不适用
The clinical impact of Nintedanib and Pirfenidone on pulmonary circulation of interstitial pneumonia: A Hyogo-IP multicenter prospective observational studyInterstitial pneumoniaJPRN-UMIN000043384Shinko Hospital75
尚未招募
3 期
intedanib the game changer in COVID 19 patientsCTRI/2021/07/035256Self